ArticleOxford medical case reports2025
Immune thrombocytopenia as a rare initial manifestation and complication of Hodgkin lymphoma: a Pediatric case report.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hodgkin lymphoma (HL) is a malignancy of the lymphatic system often associated with immune dysfunction. This case describes an 11-year-old boy presenting with epistaxis, petechiae, and thrombocytopenia (40 000/μl), initially diagnosed as immune thrombocytopenia (ITP). Further evaluation revealed lymphadenopathy and splenomegaly. A biopsy of an axillary lymph node confirmed HL, with immunohistochemical analysis identifying Reed-Sternberg cells positive for CD30 and CD15. The patient began treatment with the ABVD chemotherapy regimen, resulting in significant clinical and hematological improvement. While ITP is commonly associated with autoimmune and lymphoproliferative disorders, its occurrence as a secondary complication of HL is rare, reported in less than 1% of cases. This case emphasizes the importance of considering HL as an underlying cause in patients presenting with unexplained ITP, particularly when lymphadenopathy or systemic symptoms are observed. Prompt diagnosis and initiation of therapy are crucial for achieving positive outcomes in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.